project id: TCGA-UCEC; case submitter id: TCGA-AX-A2HH; source center: 23; state: released; a260 a280 ratio: 1.75; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.6; rna integrity number: 8.5; age at index: 60; days to birth: -21924; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1950; age at diagnosis: 21924; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 540.0; figo stage: Stage IA; icd 10 code: C54.1; last known disease status: not reported; morphology: 8380/3; primary diagnosis: Endometrioid adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Endometrium; synchronous malignancy: No; tissue or organ of origin: Endometrium; tumor grade: Not Reported; year of diagnosis: 2010; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 462; initial weight: 150.0; oct embedded: false; preservation method: Unknown; sample id: 0e73eeac-251a-43fa-9141-636262ee3129; sample submitter id: TCGA-AX-A2HH-01A; portion id: 5fcef1d5-3dfa-44bb-8333-a90bf2abb63b; portion submitter id: TCGA-AX-A2HH-01A-11; slide id: 5810b3f2-6657-4383-a153-7a619f5650c7; slide submitter id: TCGA-AX-A2HH-01A-01-TSA; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 0.0; percent necrosis: 18.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 2.0; percent tumor cells: 80.0; percent tumor nuclei: 96.0; section location: TOP;